Back to Business
Business
6 August 2026
Why This Biotech Dealmaker — Tied To Merck, Travere — Charged Higher
Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
About this report
Downunder Voices provides an independently written summary and community perspective based on information published by the original source. The original publisher remains responsible for its reporting.
Join our community
Follow Downunder Voices
Join thousands of readers following news and community stories from Australia, New Zealand and the Pacific.
